Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Merck & Co. selects antiobesity CB1 inverse agonist MK-5596 as clinical candidate

April 6, 2010

Unfavorable risk-benefit noted with anticoagulant/antiplatelet therapy in atrial fibrillation

April 6, 2010

Reduced risk for stroke and embolism with dabigatran compared to warfarin in RE-LY trial

April 6, 2010

Aldosterone synthase inhibitor LCI-699 shows promise in hypertension trial

April 6, 2010

Discovery of HCV protease inhibitor BMS-650032 described

April 1, 2010

Studies describe pharmacokinetics, interactions with renin inhibitor ACT-178882/MK-1597

April 1, 2010

Preclinical safety of oseltamivir supports clinical development in infants

April 1, 2010

Pfizer describes identification of selective 5-HT6 receptor antagonist WAY-262531

April 1, 2010

Greater blood pressure reduction seen with LCZ-696 than with valsartan in hypertension

April 1, 2010

Second-generation cholesterol absorption inhibitors discovered at Merck & Co.

March 31, 2010

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...